First Washington CORP grew its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 49.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 264,760 shares of the biopharmaceutical company’s stock after purchasing an additional 87,810 shares during the period. ACADIA Pharmaceuticals makes up approximately 2.0% of First Washington CORP’s holdings, making the stock its 18th largest holding. First Washington CORP owned approximately 0.21% of ACADIA Pharmaceuticals worth $4,043,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Stevens Capital Management LP lifted its position in ACADIA Pharmaceuticals by 4.8% during the 1st quarter. Stevens Capital Management LP now owns 61,319 shares of the biopharmaceutical company’s stock worth $1,378,000 after acquiring an additional 2,802 shares in the last quarter. New York State Common Retirement Fund lifted its position in ACADIA Pharmaceuticals by 1.7% during the 1st quarter. New York State Common Retirement Fund now owns 211,300 shares of the biopharmaceutical company’s stock worth $4,748,000 after acquiring an additional 3,500 shares in the last quarter. Point72 Asia Hong Kong Ltd lifted its position in ACADIA Pharmaceuticals by 822.9% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 4,439 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 3,958 shares in the last quarter. Xact Kapitalforvaltning AB lifted its position in ACADIA Pharmaceuticals by 37.7% during the 1st quarter. Xact Kapitalforvaltning AB now owns 15,332 shares of the biopharmaceutical company’s stock worth $345,000 after acquiring an additional 4,200 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC lifted its position in ACADIA Pharmaceuticals by 23.8% during the 1st quarter. Alpine Woods Capital Investors LLC now owns 26,000 shares of the biopharmaceutical company’s stock worth $584,000 after acquiring an additional 5,000 shares in the last quarter. 92.98% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently commented on ACAD. Zacks Investment Research raised ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. BidaskClub raised ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 23rd. HC Wainwright reissued a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Wednesday, May 16th. Piper Jaffray Companies lowered ACADIA Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $19.00 price target on the stock. in a research report on Monday, August 6th. Finally, JMP Securities reduced their price target on ACADIA Pharmaceuticals from $50.00 to $27.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $38.38.

Shares of ACAD opened at $14.42 on Friday. ACADIA Pharmaceuticals Inc. has a 52-week low of $12.77 and a 52-week high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.06). ACADIA Pharmaceuticals had a negative net margin of 135.99% and a negative return on equity of 78.56%. The business had revenue of $57.06 million during the quarter, compared to analyst estimates of $58.63 million. During the same period in the previous year, the company earned ($0.55) earnings per share. The business’s revenue for the quarter was up 87.2% on a year-over-year basis. equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post -2.1 EPS for the current year.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Further Reading: How to Invest in Marijuana Stocks

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.